PriceTargets.com logo

OTCMKTS:DSRLF - DiaSorin Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 4 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$180.75 As of 04/15/2021 11:13 PM ET
▼ -0.75 (-0.41%)
1 month | 3 months | 12 months
Get New DiaSorin Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DSRLF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DSRLF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for DiaSorin in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $180.75.
Hold
The current consensus among 6 polled investment analysts is to hold stock in DiaSorin.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 4 sell ratings
Ratings as of
1/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 4 sell ratings
Ratings as of
3/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 4 sell ratings
Ratings as of
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 4 sell ratings

DateBrokerageActionRatingPrice TargetDetails
3/24/2021Berenberg BankReiterated RatingHold
i
3/18/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight
i
12/10/2020BNP ParibasReiterated RatingUnderperform
i
12/10/2020Exane BNP ParibasReiterated RatingUnderperform
i
12/10/2020Kepler Capital MarketsUpgradeHold ➝ Buy
i
12/9/2020Morgan StanleyInitiated CoverageEqual Weight
i
10/30/2020Berenberg BankReiterated RatingHold
i
6/4/2020Berenberg BankReiterated RatingHold
i
5/26/2020Jefferies Financial GroupDowngradeHold ➝ Underperform
i
3/17/2020Berenberg BankReiterated RatingHold
i
(Data available from 4/19/2016 forward)
DiaSorin logo
DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Read More

Today's Range

Now: $180.75
$180.75
$180.75

50 Day Range

MA: $183.97
$165.00
$219.00

52 Week Range

Now: $180.75
$0.00
$232.00

Volume

100 shs

Average Volume

267 shs

Market Capitalization

$10.11 billion

P/E Ratio

50.35

Dividend Yield

N/A

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaSorin?

The following Wall Street sell-side analysts have issued research reports on DiaSorin in the last year: Berenberg Bank, BNP Paribas, Exane BNP Paribas, Jefferies Financial Group Inc., Kepler Capital Markets, Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for DSRLF.

What is the current price target for DiaSorin?

0 Wall Street analysts have set twelve-month price targets for DiaSorin in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for DiaSorin in the next year.
View the latest price targets for DSRLF.

What is the current consensus analyst rating for DiaSorin?

DiaSorin currently has 4 sell ratings, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DSRLF, but not buy more shares or sell existing shares.
View the latest ratings for DSRLF.

What other companies compete with DiaSorin?

Other companies that are similar to DiaSorin include Compass Group, Flutter Entertainment, Sands China, Seven & i, Kuehne + Nagel International, Sandvik AB (publ), H & M Hennes & Mauritz AB (publ), Experian, Japan Tobacco, Techtronic Industries, ASSA ABLOY AB (publ), Amadeus IT Group, CK Hutchison, Swire Pacific and Fujitsu.

How do I contact DiaSorin's investor relations team?

DiaSorin's physical mailing address is Via Crescentino, Saluggia L6, 13040. The company's listed phone number is 390-161-4871 and its investor relations email address is [email protected] The official website for DiaSorin is www.diasoringroup.com.